{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:21:02Z","timestamp":1794428462169,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016692","name":"Key Research and Development Program of Ningxia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2026AAC031199"],"award-info":[{"award-number":["2026AAC031199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2026AAC031176"],"award-info":[{"award-number":["2026AAC031176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2026BEG02001"],"award-info":[{"award-number":["2026BEG02001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260716"],"award-info":[{"award-number":["82260716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2025AAC030748"],"award-info":[{"award-number":["2025AAC030748"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tranon.2026.103068","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:13:26Z","timestamp":1791774806000},"page":"103068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-3754","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixia","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.tranon.2026.103068_bib0001","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.103068_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.tranon.2026.103068_bib0003","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103068_bib0004","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.tranon.2026.103068_bib0005","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103068_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10411","key":"10.1016\/j.tranon.2026.103068_bib0007","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and HER2-negative metastatic breast cancer (TROPiCS-02): a randomized, open-label, multicenter, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.tranon.2026.103068_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.tranon.2026.103068_bib0009","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with previously treated HER3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.tranon.2026.103068_bib0010","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103068_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105231","article-title":"Molecular alterations of MUC1 and their therapeutic exploitation: emerging opportunities in cancer therapy","volume":"221","author":"Khan","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tranon.2026.103068_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-026-01188-1","article-title":"Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management","author":"Peters","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.103068_bib0013","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-HER2 antibody-drug conjugate, in tumors with HER2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.103068_bib0014","article-title":"Enhanced permeability and retention (EPR) effect: advances in nanomedicine for improved tumor targeting","volume":"181","author":"Khan","year":"2026","journal-title":"Biomater. Adv."},{"issue":"8","key":"10.1016\/j.tranon.2026.103068_bib0015","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1021\/acs.molpharmaceut.5c00473","article-title":"Translational insights into stimuli-responsive magnetic nanoparticles for breast cancer treatment","volume":"22","author":"Khan","year":"2025","journal-title":"Mol. Pharmaceut."},{"issue":"12","key":"10.1016\/j.tranon.2026.103068_bib0016","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ccell.2021.09.016","article-title":"Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity","volume":"39","author":"Jing","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.103068_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103068_bib0018","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41467-025-67840-z","article-title":"Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue","volume":"17","author":"Borremans","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.103068_bib0019","article-title":"Multi-omic profiling reveals antibody-drug conjugate targetability in ovarian cancer","author":"Pollanen","year":"2026","journal-title":"medRxiv."},{"issue":"5","key":"10.1016\/j.tranon.2026.103068_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70190","article-title":"Spatial multiomics reveal insights into ADC efficacy","volume":"56","author":"Goni","year":"2026","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.tranon.2026.103068_bib0021","article-title":"A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"12","key":"10.1016\/j.tranon.2026.103068_bib0022","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","article-title":"High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging","volume":"40","author":"He","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103068_bib0023","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","article-title":"High-resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis","volume":"14","author":"Janesick","year":"2023","journal-title":"Nat. Commun."},{"issue":"6294","key":"10.1016\/j.tranon.2026.103068_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"Stahl","year":"2016","journal-title":"Science"},{"issue":"6233","key":"10.1016\/j.tranon.2026.103068_bib0025","doi-asserted-by":"crossref","first-page":"aaa6090","DOI":"10.1126\/science.aaa6090","article-title":"Spatially resolved, highly multiplexed RNA profiling in single cells","volume":"348","author":"Chen","year":"2015","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.tranon.2026.103068_bib0026","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.tranon.2026.103068_bib0027","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.tranon.2026.103068_bib0028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","article-title":"Squidpy: a scalable framework for spatial omics analysis","volume":"19","author":"Palla","year":"2022","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.tranon.2026.103068_bib0029","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"7418","key":"10.1016\/j.tranon.2026.103068_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.tranon.2026.103068_bib0031","first-page":"2674","article-title":"Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.103068_bib0032","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1186\/s12885-024-13065-0","article-title":"Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach","volume":"24","author":"Neviere","year":"2024","journal-title":"BMC. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103068_bib0033","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s40425-019-0816-5","article-title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","volume":"7","author":"MacGregor","year":"2019","journal-title":"J. ImmunOther Cancer"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326004043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326004043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:21:25Z","timestamp":1794424885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326004043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S1936523326004043"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103068","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103068"}}